Appendix 1

| <b>Cancer Waiting Times Performance Report</b>  |   |  |   |  |   |  |  |  |  |  |  |   |  |   |   |   |   |  |
|---|---|--|---|--|---|--|--|--|--|--|--|---|--|---|---|---|---|--|
| National Standards  |   |  |   |  |   |  |  |  |  |  |  | 2014-15   |  |   | 201   | 5-16  | 1   |  |
| Leeds West CCG (All Providers)  | Target  | Sep  | Q2  | Oct  | Nov   | Dec  | Q3   | Jan  | Feb  | Mar  | Q4   | Q1 + Q2 +<br>Q3 + Q4  | Apr'15   | May'15  | Jun'15  | Q1  | Jul'15  | Aug'1  |
| 2 week GP referral to 1st outpatient (suspected cancer)   | 93.0%   | 94.3%  | 93.8%   | 96.0%  | 96.8%   | 96.6%  | 96.5%  | 93.2%  | 97.9%  | 93.7%  | 94.9%  | 94.8%   | 90.2%  | 93.5%   | 92.6%   | 92.0%   | 94.7%   | 91.4%  |
| 2 week GP referral to 1st outpatient (breast symptoms)  | 93.0%   | 92.9%  | 91.9%   | 93.7%  | 96.9%   | 97.9%  | 96.1%  | 97.3%  | 95.3%  | 96.2%  | 96.2%  | 92.6%   | 88.4%  | 89.9%   | 95.1%   | 91.9%   | 91.7%   | 73.3%  |
| 31 day diagnosis to treatment for all cancers   | 96.0%   | 97.7%  | 97.9%   | 97.4%  | 99.2%   | 99.1%  | 98.6%  | 90.5%  | 96.9%  | 97.9%  | 95.5%  | 97.3%   | 97.2%  | 97.5%   | 98.6%   | 97.9%   | 99.3%   | 99.1%  |
| 31 day second or subsequent treatment- surgery  | 94.0%   | 94.6%  | 96.4%   | 92.5%  | 86.2%   | 96.4%  | 93.9%  | 84.4%  | 96.7%  | 100.0%   | 97.3%  | 96.5%   | 96.3%  | 100.0%  | 95.5%   | 97.1%   | 93.9%   | 100.0%   |
| 31 day second or subsequent treatment- drug   | 98.0%   | 100.0%   | 100.0%  | 100.0%   | 100.0%  | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%  | 100.0%   | 98.3%   | 100.0%  | 100.0%  | 100.0%  | 100.0%   |
| 1 day second or subsequent treatment- radiotherapy  | 94.0%   | 97.8%  | 98.5%   | 98.3%  | 100.0%  | 100.0%   | 99.4%  | 100.0%   | 100.0%   | 98.0%  | 99.3%  | 99.3%   | 98.1%  | 100.0%  | 100.0%  | 99.3%   | 100.0%  | 100.0%   |
| 52 days urgent GP referral to treatment of all cancers  | 85.0%   | 79.3%  | 84.2%   | 80.0%  | 78.2%   | 89.1%  | 82.9%  | 78.8%  | 73.9%  | 86.2%  | 80.1%  | 83.8%   | 91.1%  | 76.9%   | 84.9%   | 84.2%   | 84.4%   | 90.6%  |
| 52 day referral to treatment from consultant screening  | 90.0%   | 100.0%   | 97.2%   | 100.0%   | 100.0%  | 92.9%  | 97.3%  | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 98.3%   | 100.0%   | 90.0%   | 100.0%  | 96.2%   | 75.0%   | 100.09   |
| 52 day referral to treatment consultant upgrade   | 85.0%   | 100.0%   | 86.7%   | 40.0%  | 100.0%  | 60.0%  | 58.3%  | 40.0%  | 66.7%  | 85.7%  | 66.7%  | 76.4%   | 100.0%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 83.3%  |
|   |   |  |   |  |   |  |  |  |  |  |  | 2011.15   |  |   | 201   | 5-16  |   |  |
|   |   |  |   | 1  |   |  |  |  |  |  |  | 2014-15<br>Q1 + Q2 +  |  |   |   |   |   |  |
| eeds North CCG (All Providers)  | Target  | Sep  | Q2  | Oct  | Nov   | Dec  | Q3   | Jan  | Feb  | Mar  | Q4   | Q3 + Q4   | Apr'15   | May'15  | Jun'15  | Q1  | Jul'15  | Aug'1  |
| week GP referral to 1st outpatient (suspected cancer)   | 93.0%   | 95.3%  | 95.9%   | 96.2%  | 96.2%   | 95.6%  | 96.1%  | 95.7%  | 95.1%  | 93.9%  | 94.8%  | 95.3%   | 90.4%  | 94.1%   | 93.2%   | 92.5%   | 94.7%   | 94.5%  |
| week GP referral to 1st outpatient (breast symptoms)  | 93.0%   | 94.1%  | 95.6%   | 96.9%  | 98.8%   | 97.3%  | 97.7%  | 96.4%  | 92.5%  | 96.5%  | 95.3%  | 94.1%   | 94.2%  | 91.1%   | 98.9%   | 95.4%   | 93.9%   | 83.0%  |
| 1 day diagnosis to treatment for all cancers  | 96.0%   | 95.8%  | 96.4%   | 100.0%   | 97.8%   | 98.4%  | 99.1%  | 98.9%  | 97.1%  | 98.5%  | 98.3%  | 98.2%   | 98.9%  | 98.7%   | 96.9%   | 98.2%   | 98.0%   | 100.0  |
| 1 day second or subsequent treatment- surgery   | 94.0%   | 92.3%  | 95.3%   | 100.0%   | 92.3%   | 100.0%   | 100.0%   | 94.7%  | 75.0%  | 100.0%   | 92.2%  | 95.9%   | 90.9%  | 89.5%   | 100.0%  | 95.2%   | 100.0%  | 95.0%  |
| 1 day second or subsequent treatment- drug  | 98.0%   | 97.4%  | 99.1%   | 100.0%   | 100.0%  | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 99.8%   | 100.0%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0  |
| 1 day second or subsequent treatment- radiotherapy  | 94.0%   | 100.0%   | 100.0%  | 100.0%   | 100.0%  | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 96.8%  | 98.8%  | 99.4%   | 100.0%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0  |
| 2 days urgent GP referral to treatment of all cancers   | 85.0%   | 80.0%  | 77.2%   | 80.0%  | 84.8%   | 75.0%  | 80.4%  | 87.5%  | 79.3%  | 75.9%  | 81.9%  | 81.7%   | 85.7%  | 80.5%   | 75.7%   | 80.8%   | 88.9%   | 80.09  |
| 2 day referral to treatment from consultant screening   | 90.0%   | 100.0%   | 87.5%   | 100.0%   | 100.0%  | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 100.0%   | 98.0%   | 100.0%   | 100.0%  | 100.0%  | 100.0%  | 94.4%   | 93.8%  |
| 2 day referral to treatment consultant upgrade  | 85.0%   | 100.0%   | 90.9%   | 66.7%  | 100.0%  | 100.0%   | 80.0%  | 100.0%   | -  | 100.0%   | 100.0%   | 91.7%   | 100.0%   | 50.0%   | 100.0%  | 83.3%   | 100.0%  | 50.0%  |
|   |   |  |   |  |   |  |  |  |  |  |  |   |  |   | 201   | 5-16  |   |  |
|   |   |  |   |  |   |  |  |  |  |  |  | 2014-15   |  |   | 201   |   |   |  |
| eeds S&E CCG (All Providers)  | Target  | Sep  | Q2  | Oct  | Nov   | Dec  | Q3   | Jan  | Feb  | Mar  | Q4   | Q1 + Q2 +<br>Q3 + Q4  | Apr'15   | May'15  | Jun'15  | Q1  | Jul'15  | Aug'1  |
| week GP referral to 1st outpatient (suspected cancer)   | 93.0%   | 94.9%  | 93.4%   | 95.8%  | 94.4%   | 95.3%  | 95.2%  | 95.0%  | 96.3%  | 94.3%  | 95.2%  | 94.4%   | 90.5%  | 94.9%   | 92.9%   | 92.7%   | 93.8%   | 92.9%  |
| week GP referral to 1st outpatient (breast symptoms)  | 93.0%   | 96.1%  | 94.6%   | 98.1%  | 97.3%   | 98.9%  | 98.1%  | 94.2%  | 97.2%  | 97.4%  | 96.3%  | 93.7%   | 92.5%  | 91.3%   |   | 94.3%   | 93.2%   |  |
| 1 day diagnosis to treatment for all cancers  | 96.0%   | 97.8%  |   |  |   |  |  |  |  |  | 30.375   |   |  | 91.5%   | 97.9%   | 74.770  |   | 79.79  |
| 1 day second or subsequent treatment- surgery   | 94.0%   |  | 97.3%   | 93.8%  |   |  |  |  | 95.2%  | 96.1%  | 96.7%  |   |  |   | 97.9%<br>97.9%  |   |   |  |
| 1 day second or subsequent treatment- drug  | J4.U/0  |  | 97.3%<br>92.2%  | 93.8%<br>100.0%  | 97.8%   | 95.1%  | 95.7%  | 97.6%  | 95.2%<br>95.5%   | 96.1%<br>94.1%   | 96.7%<br>93.2%   | 96.8%   | 97.9%<br>100.0%  | 98.6%   | 97.9%<br>97.9%<br>100.0%  | 97.8%   | 99.2%   | 98.9%  |
|   | 98.0%   | 86.7%<br>100.0%  | 97.3%<br>92.2%<br>100.0%  | 93.8%<br>100.0%<br>100.0%  |   |  |  |  | 95.2%<br>95.5%<br>100.0%   | 96.1%<br>94.1%<br>100.0%   | 96.7%<br>93.2%<br>100.0%   |   | 97.9%  |   | 97.9%   | 97.8%<br>100.0%   |   | 98.99<br>95.59   |
|   |   | 86.7%  | 92.2%   | 100.0%   | 97.8%<br>94.1%  | 95.1%<br>93.9%   | 95.7%<br>95.3%   | 97.6%<br>90.0%   | 95.5%  | 94.1%  | 93.2%  | 96.8%<br>94.3%  | 97.9%<br>100.0%  | 98.6%<br>100.0%   | 97.9%<br>100.0%   | 97.8%   | 99.2%<br>92.9%  | 98.99<br>95.59<br>100.0  |
| 1 day second or subsequent treatment- radiotherapy  | 98.0%   | 86.7%<br>100.0%  | 92.2%<br>100.0%   | 100.0%   | 97.8%<br>94.1%<br>100.0%  | 95.1%<br>93.9%<br>100.0%   | 95.7%<br>95.3%<br>100.0%   | 97.6%<br>90.0%<br>100.0%   | 95.5%<br>100.0%  | 94.1%  | 93.2%<br>100.0%  | 96.8%<br>94.3%<br>100.0%  | 97.9%<br>100.0%<br>100.0%  | 98.6%<br>100.0%<br>98.3%  | 97.9%<br>100.0%<br>100.0%   | 97.8%<br>100.0%<br>99.4%  | 99.2%<br>92.9%<br>100.0%  | 98.99<br>95.59<br>100.0<br>100.0   |
| 1 day second or subsequent treatment- radiotherapy<br>2 days urgent GP referral to treatment of all cancers   | 98.0%<br>94.0%  | 86.7%<br>100.0%<br>100.0%  | 92.2%<br>100.0%<br>100.0%   | 100.0%<br>100.0%<br>95.3%  | 97.8%<br>94.1%<br>100.0%<br>100.0%  | 95.1%<br>93.9%<br>100.0%<br>100.0%   | 95.7%<br>95.3%<br>100.0%<br>98.0%  | 97.6%<br>90.0%<br>100.0%<br>100.0%   | 95.5%<br>100.0%<br>100.0%  | 94.1%<br>100.0%<br>100.0%  | 93.2%<br>100.0%<br>100.0%  | 96.8%<br>94.3%<br>100.0%<br>99.5%   | 97.9%<br>100.0%<br>100.0%<br>100.0%  | 98.6%<br>100.0%<br>98.3%<br>100.0%  | 97.9%<br>100.0%<br>100.0%<br>100.0%   | 97.8%<br>100.0%<br>99.4%<br>100.0%  | 99.2%<br>92.9%<br>100.0%<br>100.0%  | 98.99<br>95.59<br>100.0<br>100.0<br>91.39  |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening  | 98.0%<br>94.0%<br>85.0%   | 86.7%<br>100.0%<br>100.0%<br>63.9%   | 92.2%<br>100.0%<br>100.0%<br>77.8%  | 100.0%<br>100.0%<br>95.3%<br>84.0%   | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%   | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%  | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%   | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%  | 95.5%<br>100.0%<br>100.0%<br>78.9%   | 94.1%<br>100.0%<br>100.0%<br>83.9%   | 93.2%<br>100.0%<br>100.0%<br>79.1%   | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%  | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>91.7%                                       | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%   | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>87.2%  | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%   | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%   | 98.9%<br>95.5%<br>100.0°<br>100.0°<br>91.3%  |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade   | 98.0%<br>94.0%<br>85.0%<br>90.0%  | 86.7%<br>100.0%<br>100.0%<br>63.9%<br>75.0%  | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%   | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%   | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%  | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%  | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%  | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%  | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%  | 94.1%<br>100.0%<br>100.0%<br>83.9%<br>100.0%   | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%   | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%   | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>91.7%<br>100.0%                             | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%<br>100.0%   | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>87.2%<br>100.0%<br>50.0%                                   | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%  | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%  | 98.9%<br>95.5%<br>100.0<br>100.0<br>91.3%<br>100.0   |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade   | 98.0%<br>94.0%<br>85.0%<br>90.0%  | 86.7%<br>100.0%<br>100.0%<br>63.9%<br>75.0%  | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%   | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%   | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%  | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%  | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%  | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%  | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%  | 94.1%<br>100.0%<br>100.0%<br>83.9%<br>100.0%   | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%   | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%  | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>91.7%<br>100.0%                             | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%<br>100.0%   | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>87.2%<br>100.0%<br>50.0%                                   | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%   | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%  | 98.99<br>95.59<br>100.0<br>100.0<br>91.39<br>100.0   |
| L day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade ancer Waiting Times performance   | 98.0%<br>94.0%<br>85.0%<br>90.0%  | 86.7%<br>100.0%<br>100.0%<br>63.9%<br>75.0%  | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%   | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%   | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%  | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%  | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%  | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%  | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%  | 94.1%<br>100.0%<br>100.0%<br>83.9%<br>100.0%   | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%   | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%  | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>91.7%<br>100.0%                             | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%<br>100.0%   | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>87.2%<br>100.0%<br>50.0%                                   | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%  | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%  | 98.99<br>95.59<br>100.0<br>100.0<br>91.39<br>100.0<br>100.0  |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade  ancer Waiting Times performance  THT Trust Total  week GP referral to 1st outpatient (suspected cancer)  | 98.0%<br>94.0%<br>85.0%<br>90.0%<br>85.0%<br>Target                                     | 86.7%<br>100.0%<br>100.0%<br>63.9%<br>75.0%<br>100.0%<br>Sep                                     | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%  | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct   | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov  | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>Dec   | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%   | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>Jan<br>93.9%  | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%  | 94.1%<br>100.0%<br>100.0%<br>83.9%<br>100.0%<br>Mar<br>93.6%                             | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>Q4   | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%<br>2014-15<br>Q1 + Q2 +<br>Q3 + Q4<br>94.6%  | 97.9%<br>100.0%<br>100.0%<br>100.0%<br>91.7%<br>100.0%<br>Apr'15                   | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%<br>100.0%<br>66.7%<br>May'15  | 97.9% 100.0% 100.0% 100.0% 87.2% 100.0% 50.0%  201:  Jun'15 92.5%                                 | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%<br>5-16<br>Q1  | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%<br>85.7%   | 98.99<br>95.59<br>100.0<br>100.0<br>91.39<br>100.0<br>100.0<br>Aug'1   |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade  ancer Waiting Times performance  THT Trust Total  week GP referral to 1st outpatient (suspected cancer) week GP referral to 1st outpatient (breast symptoms)   | 98.0%<br>94.0%<br>85.0%<br>90.0%<br>85.0%<br>Target<br>93.0%                            | 86.7% 100.0% 100.0% 63.9% 75.0% 100.0%  Sep 94.5% 93.6%  | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%<br>Q2<br>94.3%<br>93.4%  | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct<br>95.7%<br>94.5%   | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov<br>95.4%<br>97.4%                                      | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>Dec<br>96.0%<br>98.3%   | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%<br>Q3<br>95.7%<br>96.6%   | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>Jan<br>93.9%<br>96.0%                               | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%<br>Feb   | 94.1%<br>100.0%<br>100.0%<br>83.9%<br>100.0%<br>100.0%<br>Mar<br>93.6%<br>96.0%          | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>100.0%<br>Q4<br>94.6%<br>95.6%   | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%<br>2014-15<br>Q1 + Q2 +<br>Q3 + Q4<br>94.6%<br>92.7%   | 97.9%<br>100.0%<br>100.0%<br>91.7%<br>100.0%<br>100.0%<br>Apr'15<br>90.6%<br>90.8% | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%<br>100.0%<br>66.7%<br>May'15<br>93.6%<br>91.3%                            | 97.9% 100.0% 100.0% 87.2% 100.0% 50.0%  2019  Jun'15  92.5% 96.8%                                 | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%<br>5-16<br>Q1<br>92.2%<br>93.5%  | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%<br>85.7%<br>Jul'15<br>94.3%<br>91.9%                                       | 98.99<br>95.59<br>100.0<br>100.0<br>91.39<br>100.0<br>100.0<br>Aug'1<br>91.89<br>73.79                                     |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade  ancer Waiting Times performance  THT Trust Total  week GP referral to 1st outpatient (suspected cancer) week GP referral to 1st outpatient (breast symptoms) 1 day diagnosis to treatment for all cancers  | 98.0%<br>94.0%<br>85.0%<br>90.0%<br>85.0%<br>Target<br>93.0%<br>93.0%                   | 86.7%<br>100.0%<br>100.0%<br>63.9%<br>75.0%<br>100.0%<br>Sep<br>94.5%<br>93.6%                   | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%<br>Q2<br>94.3%<br>93.4%<br>96.2%                                     | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct<br>95.7%<br>94.5%<br>95.6%                                      | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov<br>95.4%<br>97.4%                                      | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>100.0%<br>Dec<br>96.0%<br>98.3%<br>97.0%                                      | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%<br>Q3<br>95.7%<br>96.6%<br>96.5%                                      | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>Jan<br>93.9%<br>96.0%<br>94.0%                      | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%<br>Feb<br>96.4%<br>94.9%   | 94.1% 100.0% 100.0% 83.9% 100.0%  Mar  93.6% 96.0% 97.5%                                 | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>100.0%<br>Q4<br>94.6%<br>95.6%<br>96.0%                                | 96.8% 94.3% 100.0% 99.5% 80.0% 93.0% 86.0%  2014-15 Q1 + Q2 + Q3 + Q4  94.6% 92.7% 96.5%  | 97.9% 100.0% 100.0% 91.7% 100.0% 100.0% 4pr'15 90.6% 90.8%                         | 98.6% 100.0% 98.3% 100.0% 93.1% 100.0% 66.7%  May'15  93.6% 91.3% 97.1%   | 97.9% 100.0% 100.0% 87.2% 100.0% 50.0%  2019  Jun'15  92.5% 96.8% 97.4%                           | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%<br>5-16<br>Q1<br>92.2%<br>93.5%<br>97.0%                                     | 99.2%<br>92.9%<br>100.0%<br>87.0%<br>85.7%<br>85.7%<br>Jul'15<br>94.3%<br>91.9%   | 98.95<br>95.55<br>100.0<br>100.0<br>91.35<br>100.0<br>100.0<br>Aug'1<br>91.85<br>73.79<br>99.35                            |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade  ancer Waiting Times performance  THT Trust Total  week GP referral to 1st outpatient (suspected cancer) week GP referral to 1st outpatient (breast symptoms) 1 day diagnosis to treatment for all cancers 1 day second or subsequent treatment- surgery  | 98.0%<br>94.0%<br>85.0%<br>90.0%<br>85.0%<br>Target<br>93.0%<br>93.0%<br>96.0%<br>94.0% | 86.7%<br>100.0%<br>100.0%<br>63.9%<br>75.0%<br>100.0%<br>Sep<br>94.5%<br>93.6%<br>95.7%<br>92.1% | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%<br>Q2<br>94.3%<br>93.4%<br>96.2%<br>94.4%                            | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct<br>95.7%<br>94.5%<br>95.6%<br>94.9%                             | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov<br>95.4%<br>97.4%<br>96.4%<br>89.4%                    | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>100.0%<br>Dec<br>96.0%<br>98.3%<br>97.0%<br>94.5%                             | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%<br>Q3<br>95.7%<br>96.6%<br>96.5%<br>94.3%                             | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>Jan<br>93.9%<br>96.0%<br>94.0%<br>89.0%             | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%<br>Feb<br>96.4%<br>94.9%<br>94.8%<br>93.5%                             | 94.1% 100.0% 100.0% 83.9% 100.0%  Mar  93.6% 96.0% 97.5% 98.4%                           | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>100.0%<br>Q4<br>94.6%<br>95.6%<br>96.0%                                | 96.8% 94.3% 100.0% 99.5% 80.0% 93.0% 86.0%  - 2014-15 Q1 + Q2 + Q3 + Q4  94.6% 92.7% 96.5% 94.8%  | 97.9% 100.0% 100.0% 91.7% 100.0% 100.0%  4pr'15 90.6% 90.8% 95.4%                  | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%<br>100.0%<br>66.7%<br>May'15<br>93.6%<br>91.3%<br>97.1%<br>98.6%          | 97.9% 100.0% 100.0% 100.0% 87.2% 100.0% 50.0%  201:  Jun'15  92.5% 96.8% 97.4% 98.3%              | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%<br>5-16<br>Q1<br>92.2%<br>93.5%<br>97.0%<br>97.6%                            | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%<br>85.7%<br>Jul'15<br>94.3%<br>91.9%<br>97.7%                              | 98.95<br>95.55<br>100.0<br>100.0<br>91.35<br>100.0<br>100.0<br>Aug'1<br>91.85<br>73.75<br>99.35<br>97.05                   |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade  ancer Waiting Times performance  THT Trust Total  week GP referral to 1st outpatient (suspected cancer) week GP referral to 1st outpatient (breast symptoms) 1 day diagnosis to treatment for all cancers 1 day second or subsequent treatment- surgery 1 day second or subsequent treatment- drug   | 98.0%<br>94.0%<br>85.0%<br>90.0%<br>85.0%<br>Target<br>93.0%<br>93.0%<br>94.0%<br>94.0% | 86.7% 100.0% 100.0% 63.9% 75.0% 100.0%  Sep 94.5% 93.6% 95.7% 92.1% 99.6%                        | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%<br>Q2<br>94.3%<br>93.4%<br>96.2%<br>94.4%<br>99.9%                   | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct<br>95.7%<br>94.5%<br>95.6%<br>94.9%<br>100.0%                   | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov<br>95.4%<br>97.4%<br>96.4%<br>89.4%<br>100.0%          | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>100.0%<br>Dec<br>96.0%<br>98.3%<br>97.0%<br>94.5%<br>100.0%                   | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%<br>Q3<br>95.7%<br>96.6%<br>96.5%<br>94.3%<br>100.0%                   | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>Jan<br>93.9%<br>96.0%<br>94.0%<br>89.0%<br>100.0%   | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%<br>Feb<br>96.4%<br>94.9%<br>94.8%<br>93.5%<br>100.0%                   | 94.1% 100.0% 100.0% 83.9% 100.0% 100.0%  Mar  93.6% 96.0% 97.5% 98.4% 100.0%             | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>100.0%<br>Q4<br>94.6%<br>95.6%<br>96.0%<br>95.7%<br>100.0%             | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%<br>2014-15<br>Q1 + Q2 +<br>Q3 + Q4<br>94.6%<br>92.7%<br>96.5%<br>94.8%<br>100.0%                   | 97.9% 100.0% 100.0% 91.7% 100.0% 100.0%  Apr'15  90.6% 90.8% 96.6% 95.4% 100.0%    | 98.6%<br>100.0%<br>98.3%<br>100.0%<br>93.1%<br>100.0%<br>66.7%<br>May'15<br>93.6%<br>91.3%<br>97.1%<br>98.6%<br>99.2% | 97.9% 100.0% 100.0% 100.0% 87.2% 100.0% 50.0%  2011  Jun'15  92.5% 96.8% 97.4% 98.3% 100.0%       | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%<br>5-16<br>Q1<br>92.2%<br>93.5%<br>97.0%<br>97.6%<br>99.9%                   | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%<br>85.7%<br>Jul'15<br>94.3%<br>91.9%<br>97.7%<br>95.8%<br>100.0%           | 98.99<br>95.59<br>100.0<br>100.0<br>91.39<br>100.0<br>100.0<br>4ug'1<br>91.89<br>73.79<br>99.39<br>97.09<br>100.0          |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade 2 day referral to treatment consultant upgrade 3 day referral to treatment consultant upgrade 4 day referral to 1 day outpatient (suspected cancer) 4 week GP referral to 1 day outpatient (breast symptoms) 5 day diagnosis to treatment for all cancers 6 day second or subsequent treatment- surgery 6 day second or subsequent treatment- drug 6 day second or subsequent treatment- radiotherapy         | 98.0%<br>94.0%<br>85.0%<br>90.0%<br>85.0%<br>Target<br>93.0%<br>94.0%<br>94.0%          | 86.7% 100.0% 100.0% 63.9% 75.0% 100.0%  Sep 94.5% 93.6% 95.7% 99.6% 99.3%                        | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%<br>Q2<br>94.3%<br>93.4%<br>96.2%<br>94.4%<br>99.9%<br>99.4%          | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct<br>95.7%<br>94.5%<br>95.6%<br>94.9%<br>100.0%<br>98.4%          | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov<br>95.4%<br>97.4%<br>96.4%<br>89.4%<br>100.0%          | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>100.0%<br>Dec<br>96.0%<br>98.3%<br>97.0%<br>94.5%<br>100.0%<br>99.3%          | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%<br>Q3<br>95.7%<br>96.6%<br>96.5%<br>94.3%<br>100.0%<br>99.3%          | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>Jan<br>93.9%<br>96.0%<br>94.0%<br>89.0%<br>100.0%   | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%<br>Feb<br>96.4%<br>94.9%<br>94.8%<br>93.5%<br>100.0%<br>99.1%          | 94.1% 100.0% 100.0% 83.9% 100.0%  100.0%  Mar  93.6% 96.0% 97.5% 98.4% 100.0% 99.7%      | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>100.0%<br>94.6%<br>95.6%<br>96.0%<br>95.7%<br>100.0%<br>99.9%          | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%<br>2014-15<br>Q1 + Q2 +<br>Q3 + Q4<br>94.6%<br>92.7%<br>96.5%<br>94.8%<br>100.0%<br>99.5%          | 97.9% 100.0% 100.0% 91.7% 100.0% 100.0%  Apr'15  90.6% 90.8% 95.4% 100.0% 98.9%    | 98.6% 100.0% 98.3% 100.0% 93.1% 100.0% 66.7%  May'15  93.6% 91.3% 97.1% 98.6% 99.2% 98.9%                             | 97.9% 100.0% 100.0% 100.0% 87.2% 100.0% 50.0%  201!  Jun'15  92.5% 96.8% 97.4% 98.3% 100.0% 99.8% | 97.8% 100.0% 99.4% 100.0% 89.7% 100.0% 70.0%  5-16  Q1 92.2% 93.5% 97.0% 97.6% 99.9% 99.2%  | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%<br>85.7%<br>Jul'15<br>94.3%<br>91.9%<br>97.7%<br>95.8%<br>100.0%<br>100.0% | 98.99<br>95.59<br>100.0<br>100.0<br>91.39<br>100.0<br>100.0<br>4ug'1<br>91.89<br>73.79<br>99.39<br>97.09<br>100.0<br>99.19 |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade  Cancer Waiting Times performance  THT Trust Total  week GP referral to 1st outpatient (suspected cancer) week GP referral to 1st outpatient (breast symptoms) 1 day diagnosis to treatment for all cancers 1 day second or subsequent treatment- surgery 1 day second or subsequent treatment- drug 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers | 98.0% 94.0% 85.0% 90.0% 85.0%  Target  93.0% 96.0% 94.0% 94.0% 85.0%                    | 86.7% 100.0% 100.0% 63.9% 75.0% 100.0%  Sep 94.5% 93.6% 95.7% 92.1% 99.6% 99.3% 71.5%            | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%<br>Q2<br>94.3%<br>93.4%<br>96.2%<br>94.4%<br>99.9%<br>99.4%<br>76.2% | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct<br>95.7%<br>94.5%<br>95.6%<br>94.9%<br>100.0%<br>98.4%<br>72.1% | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov<br>95.4%<br>97.4%<br>96.4%<br>89.4%<br>100.0%<br>77.1% | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>100.0%<br>Dec<br>96.0%<br>98.3%<br>97.0%<br>94.5%<br>100.0%<br>99.3%<br>74.1% | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%<br>Q3<br>95.7%<br>96.6%<br>96.5%<br>94.3%<br>100.0%<br>99.3%<br>74.8% | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>3.9%<br>96.0%<br>94.0%<br>89.0%<br>100.0%<br>100.0% | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%<br>Feb<br>96.4%<br>94.9%<br>94.8%<br>93.5%<br>100.0%<br>99.1%<br>67.2% | 94.1% 100.0% 100.0% 83.9% 100.0% 100.0%  Mar  93.6% 96.0% 97.5% 98.4% 100.0% 99.7% 78.9% | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>100.0%<br>94.6%<br>95.6%<br>96.0%<br>95.7%<br>100.0%<br>99.9%<br>73.9% | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%<br>2014-15<br>Q1 + Q2 +<br>Q3 + Q4<br>94.6%<br>92.7%<br>96.5%<br>94.8%<br>100.0%<br>99.5%<br>76.0% | 97.9% 100.0% 100.0% 91.7% 100.0% 100.0%  Apr'15  90.6% 90.8% 95.4% 100.0% 83.2%    | 98.6% 100.0% 98.3% 100.0% 93.1% 100.0% 66.7%  May'15  93.6% 91.3% 97.1% 98.6% 99.2% 98.9% 74.2%                       | 97.9% 100.0% 100.0% 87.2% 100.0% 50.0%  201!  Jun'15  92.5% 96.8% 97.4% 98.3% 100.0% 99.8% 79.4%  | 97.8%<br>100.0%<br>99.4%<br>100.0%<br>89.7%<br>100.0%<br>70.0%<br>5-16<br>Q1<br>92.2%<br>93.5%<br>97.0%<br>97.6%<br>99.9%<br>99.2%<br>79.0% | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%<br>85.7%<br>94.3%<br>91.9%<br>97.7%<br>95.8%<br>100.0%<br>81.3%            | 98.9% 95.5% 100.09 91.3% 100.09 100.09 4ug'1 91.8% 73.7% 99.3% 97.0% 100.09 99.1% 82.5%                                    |
| 1 day second or subsequent treatment- radiotherapy 2 days urgent GP referral to treatment of all cancers 2 day referral to treatment from consultant screening 2 day referral to treatment consultant upgrade  Cancer Waiting Times performance  THT Trust Total  week GP referral to 1st outpatient (suspected cancer) week GP referral to 1st outpatient (breast symptoms) 1 day diagnosis to treatment for all cancers 1 day second or subsequent treatment- surgery 1 day second or subsequent treatment- drug 1 day second or subsequent treatment- radiotherapy   | 98.0%<br>94.0%<br>85.0%<br>90.0%<br>85.0%<br>Target<br>93.0%<br>94.0%<br>94.0%          | 86.7% 100.0% 100.0% 63.9% 75.0% 100.0%  Sep 94.5% 93.6% 95.7% 99.6% 99.3%                        | 92.2%<br>100.0%<br>100.0%<br>77.8%<br>88.9%<br>87.5%<br>Q2<br>94.3%<br>93.4%<br>96.2%<br>94.4%<br>99.9%<br>99.4%          | 100.0%<br>100.0%<br>95.3%<br>84.0%<br>100.0%<br>66.7%<br>Oct<br>95.7%<br>94.5%<br>95.6%<br>94.9%<br>100.0%<br>98.4%          | 97.8%<br>94.1%<br>100.0%<br>100.0%<br>84.6%<br>60.0%<br>50.0%<br>Nov<br>95.4%<br>97.4%<br>96.4%<br>89.4%<br>100.0%          | 95.1%<br>93.9%<br>100.0%<br>100.0%<br>76.2%<br>100.0%<br>100.0%<br>Dec<br>96.0%<br>98.3%<br>97.0%<br>94.5%<br>100.0%<br>99.3%          | 95.7%<br>95.3%<br>100.0%<br>98.0%<br>82.1%<br>77.8%<br>71.4%<br>Q3<br>95.7%<br>96.6%<br>96.5%<br>94.3%<br>100.0%<br>99.3%          | 97.6%<br>90.0%<br>100.0%<br>100.0%<br>72.7%<br>100.0%<br>100.0%<br>Jan<br>93.9%<br>96.0%<br>94.0%<br>89.0%<br>100.0%   | 95.5%<br>100.0%<br>100.0%<br>78.9%<br>60.0%<br>100.0%<br>Feb<br>96.4%<br>94.9%<br>94.8%<br>93.5%<br>100.0%<br>99.1%          | 94.1% 100.0% 100.0% 83.9% 100.0%  100.0%  Mar  93.6% 96.0% 97.5% 98.4% 100.0% 99.7%      | 93.2%<br>100.0%<br>100.0%<br>79.1%<br>100.0%<br>100.0%<br>94.6%<br>95.6%<br>96.0%<br>95.7%<br>100.0%<br>99.9%          | 96.8%<br>94.3%<br>100.0%<br>99.5%<br>80.0%<br>93.0%<br>86.0%<br>2014-15<br>Q1 + Q2 +<br>Q3 + Q4<br>94.6%<br>92.7%<br>96.5%<br>94.8%<br>100.0%<br>99.5%          | 97.9% 100.0% 100.0% 91.7% 100.0% 100.0%  Apr'15  90.6% 90.8% 95.4% 100.0% 98.9%    | 98.6% 100.0% 98.3% 100.0% 93.1% 100.0% 66.7%  May'15  93.6% 91.3% 97.1% 98.6% 99.2% 98.9%                             | 97.9% 100.0% 100.0% 100.0% 87.2% 100.0% 50.0%  201!  Jun'15  92.5% 96.8% 97.4% 98.3% 100.0% 99.8% | 97.8% 100.0% 99.4% 100.0% 89.7% 100.0% 70.0%  5-16  Q1 92.2% 93.5% 97.0% 97.6% 99.9% 99.2%  | 99.2%<br>92.9%<br>100.0%<br>100.0%<br>87.0%<br>85.7%<br>85.7%<br>Jul'15<br>94.3%<br>91.9%<br>97.7%<br>95.8%<br>100.0%<br>100.0% | 79.2% 98.9% 95.5% 100.09 100.09 91.3% 100.09 100.09  Aug'1. 91.8% 73.7% 99.3% 97.0% 100.09 99.1% 82.5% 96.6% 90.2%         |

| Current | Aug'15    |          |
|---------|-----------|----------|
| Seen    |           |          |
| within  | Referrals | Breaches |
| target  |           |          |
| 903     | 988       | 85       |
| 126     | 172       | 46       |
| 114     | 115       | 1        |
| 29      | 29        | 0        |
| 72      | 72        | 0        |
| 28      | 28        | 0        |
| 58      | 64        | 6        |
| 1       | 1         | 0        |
| -       | e         | 1        |

| Current | Aug'15    |          |
|---------|-----------|----------|
| Seen    |           |          |
| within  | Referrals | Breaches |
| target  |           |          |
| 497     | 526       | 29       |
| 73      | 88        | 15       |
| 70      | 70        | 0        |
| 19      | 20        | 1        |
| 39      | 39        | 0        |
| 21      | 21        | 0        |
| 24      | 30        | 6        |
| 15      | 16        | 1        |
| 1       | 2         | 1        |

| Current | Aug'15    |          |
|---------|-----------|----------|
| Seen    |           |          |
| within  | Referrals | Breaches |
| target  |           |          |
| 624     | 672       | 48       |
| 114     | 144       | 30       |
| 93      | 94        | 1        |
| 21      | 22        | 1        |
| 55      | 55        | 0        |
| 35      | 35        | 0        |
| 42      | 46        | 4        |
| 4       | 4         | 0        |
| 10      | 10        | 0        |

| Current | Aug'15    |          |
|---------|-----------|----------|
| Seen    |           | 7108 23  |
| within  | Referrals | Breaches |
| target  |           |          |
| 1819    | 1982      | 163      |
| 269     | 365       | 96       |
| 428     | 431       | 3        |
| 160     | 165       | 5        |
| 221     | 221       | 0        |
| 347     | 350       | 3        |
| 130     | 158       | 28       |
| 28      | 29        | 1        |
| 19      | 21        | 2        |